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1100-41 An Angiogrsphic Risk Score Integrating Both Epicardial 
and Tissue Level Perfusion Before and After Faci l i tated 
Percutaneous Coronary Intervention in Acute MI 
Michael Gibson, Sabina A. Murphy, Susan J. Marble, Staven P. Gourlay, Raymond 
Gibbons, Hal V. Barron, Harvard Clinical Research Institute, Boston, Massachusetts. 
Background: Both epicardial and tissue level parfuslon have been related to cliolcaJ out- 
comes in the setting of acute myocardial infarction (AMI), and the performance of adjunctive/ 
rescue parcutaneous intervention may alter clinical outcomes after thrombolytic administra- 
tion. Objectives & Methods: The goal of this study was to develop a simple, broadly appli- 
cable method that integrates epicardial and tissue level perfusion both before and after PCI 
to arrive at a single angiographic risk score (ARS) in patients undergoing PCI after thrembol- 
ysis. The anglographic risk score is the arithmetic sum of the TIMI Flow Grade (0-3) added to 
the TIMI Myocardial Perfusion Grade (0-3) before and after PCI (total possible score of 0- 
12). This risk score was evaluated in patients from the LIMIT AMI trial of tPA monotherapy vs 
tPA plus rhuMAb CD18. Infarct size was assessed using 120-216 hr post-AMI SPECT Tech- 
netium-99m Sestamibi data. Results: Those patients with an anglographic risk score in the 
lowest group (0-6) had a risk of 30 day death or MI of 9.3% (5/54), whereas those with an 
ARS of 7-12 had a risk of 1.3% (1/79)(p=0.04). There were no deaths or recurrent MIs 
among patients with a risk score greater than 10. Likewise, larger SPECT infarct sizes were 
observed among patients with an ARS of 0-6 (22.6% + 20.4%, n=53) compared to those 
patients with an ARS of 7-12 (12.3% + 14,3%, n=71, p--0.001). In a second analysis, data 
from patients who did not undergo PCI was incorporated by using the final TIMI Flow Grade 
and the final TIMJ Myocardial Peffusion Grade on diagnostic arteriography instead of the 
post PCI values, and similar results were seen: the risk of 30 day death or MI was 11.7% (11/ 
94) for ARS of 0-6, whereas it was 4.2% (6/143) for ARS of 7-12. SPECT infarct sizes were 
larger for ARS of 0-6 (21.0 + 19.0, n=84) vs ARS of 7-12 (11.8 + 15.2, n=127, p=0.0001). 
Conclusione: The angiographic risk score integrates indexes of epicardial and tissue level 
perfusion before and after PCI or at the end of diagnostic cardiac catheterization to arrive at 
a single risk estimate that is associated with infarct size and 30 day death or Ml. Failure to 
achieve an ARS of > 6 is associated with a doubling of infarct size. 
1100-42 Myocardial Perfusion in Pat ients  With Non-ST-Segment 
Elevation Acute Coronary Syndrome Assessed With 
Venous Contrast Echocardiography 
Christian Firschke, Marzenna Zlelinska, Stafan Martinoff, Peter Andrassy, Markus 
Schwaiger, Albert Sch6mig, Deutsches Herzzentrum, M(Jnchen, Germany. 
Non ST segment elevation acute coronary syndrome (NSTEACS) is a dynamic condition and 
the underlying pathophyslology is currently thought o comprise not only atherosderotic plaque 
rupture and supedml:x~=d thrombosis of an epicardial coronary artery but also microvasoular 
obstruction to flow due to vasoconstriction, microemboUsation a d adherence of activated blood 
cells to microvascular endothelium. We therefore sought to compare venous myocardial contrast 
echecardiography (VMCE), a new bedside technique allowing for exclusive imaging myocardial 
vascutsture, to Sestamibi SPECT (SI), angiographic and biochemical findings in patients with 
NSTEACS. 
60 patients (women, n=15, age 65-zlly) with typical anginal chest pain at rest or during minimal 
physiceJ activity plus either transient EKG changes (w~hout ST segment elevation) or elevated 
Troponin T (> 0.03 pg/ml) on presentation were included in the study. All patients underwent 
VMCE (3ml Optison in 27ml NaCI, 200m~, intermittent harmonic imaging every 5th endsystole, 
off-line digital image precessmg), SI and coronary angiography within 1 hour after presentation. 
52/60 patients (87%) had myocardial contrast defects on VMCE. Concordance with respect o 
presence of myocardial defects on SI was 88% (k=0.74). 26/60 patients (43%) had TIMI flow <3; 
all of these patients had a contrast defect on VMCE and 17/26 patients (65%) had elevated 
Troponin I. 34/60 patients (57%) had TIMI flow 3; 26/34 patients (76%) had a conf~'ast defect on 
VMCE and 14/34 patients (41%) had elevated Troponin I. 
We conclude that VMCE is a promising method for evaluation of myocardial parlusicn in patients 
with NSTEACS. It is reasonable to further invsetigate ~ role for diagnostic workup and follow up 
of patients with NSTEACS. 
1100-43 S ign i f icant  Myocardial Salvage in Patients With Non-ST 
Elevation Myocardial Infarction Is Common: Results 
Using Serial Myocardial Perfusion Imaging 
Michael C. Kontos. Karen A. Kurdzial, Joseph P. Ornato, Robert L. Jesse, James L. 
Tatum, MCV/VCU, Richmond, Virginia. 
Background: Technatium-99m sestamibi can delineate both myocardium at risk and final 
infarct size in patient (pts) with myocardial infarction (MI). Serial myocardial perfusion imag- 
ing (MPI) in pts with non-ST elevation MI has net been described previously. Methods: Pts 
with non-ST elevation MI who had MPI at the time of Emergency Department (ED) presen- 
tation were included. Percent defect size was quantitated using a 50% threshold derived 
from a phantom (r=0.99) using multiple short axis slices. Myocardial risk area was defined 
as the initial defect size; infarct area as the defect size on repeat MPI; and myocardial sal- 
vage as the difference between the two. Ejection fraction (EF) was calculated using a pre- 
viously validated computer algorithm (QGS). Results: There were 69 pts who had acute 
ED MPI and MI who underwent repeat MPI a median 5 days later. Revasculadzation was 
performed in 46 pts (67%) (only 2 within 12 hours of presentation). Variation in both mean 
peak CK (704±t223 U/L, median 377 U/L, range 91 to 9319 U/L) and risk area (19±10%, 
median 19%, range 2-46%) was high. Mean final infarct size, 11++9% (median 9%, range 
0-35%), was significantly smaller (p<0.001), and was only 57% of the initial dsk area. Sig- 
nificant salvage (initial risk area-final infarct size >25%) occurred in most pts (67%), with 
54% of pts having > 50% salvage. Pts with significant salvage had an increase in EF (48 to 
55%, 22% increase, p<0.01), while those without significant salvage EF decreased (49 to 
48%, 2% decrease, p=NS). Conclusions: The ischemic risk area in pts with non-ST eleva- 
tion MI can be large. Significant myocardial salvage is common, is not limited to those that 
have early revasculadzation, and is associated with improved EF. 
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1100-44 Old Age and Myocardial In farct  Size in the Reperfusion 
Era 
Robed A. Kloner. Ken Pools, Thomas Shook, Karin Przyktsnk, Kitty PerrJtt, Good 
Samaritan Hospital, Los Angeles, California, University of Southern California, Los 
Angeles, California. 
It is well established that cardiac death and complications are more common in elderly 
patients who suffer myocardial infarction. Although the mechanism for this increased 
morbidity and morality is unknown, one potential explanation, extrapolated from some 
experimental models of myocardial iscbomia/repeffusion, is that an age-associated 
increase in infarct size may play a role. Data on infract size in old versus young patients 
are lacking. We examined whether CK-MB determined myocardial infarct size differed in 
elderly (65 years or older) versus younger (< 65 years old) patients who did not have cor. 
onary reperfuslon (from the prethrcmbolytic era MILLS study) and from the more recent 
thrombolytic TIMI 4 trial. Infarct size data in MILLS (MB infarct size index = area under 
MB-CK curve adjusted for body surface area) was collected in 639 patients < 65 and 213 
elderly patients. Mean MB infarct size index was 15.59 _+ 0.59 Units for those < 65 and 
11.89 ± 033 Units for eldedy patients (p = 0.0003). Infarct size data in TIMI 4 (MB-CK = 
average MBoCK over first 14 hours) was collected in 260 patients < 65 and 140 elderly 
patients. Mean MB-CK infarct size was 123.2 ± 8.3 Intamational Units per liter (IU/L) in 
patients < 65 and 119.5 ± 10.4 IU/L for elderly patients (p = 0.78). The smaller infarcts in 
older MILLS patients were not due to lower presenting heart rates which were 793 boats/ 
rain (mean) in elderly patients and 80.4 for younger patients (p = NS); mean heart rates 
in TIMI 4 were 73.4 in elderly patient and 71.1 in younger patients (p = NS). These data 
suggest that in the absence of reperfusion, infract size is smaller (rather than larger) in 
older patients. Reperfusion changes this relationship reeufling in equally sized infarcts in 
old versus young, suggesting that in the reperfuslon era, infarct size is not larger in eld- 
erly patients and probably does not contribute to their worse outcome. 
1100-45 Rar i ty of  C i rcumf lex  Culpr i ts  in ST-Elevat ion MI is Due 
to Relative ECG Silence 
Thanh T. Nouven. Simon R. Dixon, John A. Fry, William W. O'Neill, Cindy L. Grines, 
James A. Goldstein, William Beaumont Hospital, Royal Oak, Michigan. 
Background: Angiographlo studies of ST-elevation myocardial infarction (MI) consis- 
tently document hat the left circumflex coronary artery (CFX) is uncommonly the culprit 
vessel compared to the left anterior descending (LAD) and the right coronary (RCA). 
Since there is no a priori reason to expect a differential propensity of the three coronary 
vessels to acute plaque instability, we hypothesized that this disparity of CFX culprits 
may result from ECG insensitivity in detection of lateral wall transmural ischemia. If this 
hypothesis is correct, the distribution of culprit vessels in non ST-elevation acute coro- 
nary syndromes(ACS) would be expected to be relatively even. Methods: We retrospec- 
tively analyzed angiograms from our cath lab database to identify the culprit vessel in 
166 pts with ST-elevation MI and in 134 others with non-ST elevation ACS. Results: In 
pts with ST-elevation MI, the CFX was uncommonly the culpdt vessel (12%), compared 
to LAD (43%) or RCA (45%) involvement (CFX vs LAD or RCA, p<0.001), However, in 
pts with non-ST elevation ACS, the distdbution of culprit vessels was more even and in 
fact the CFX was most frequently the culprit vessel (40%), whereas the LAD was respon- 
sible in 28% of pts and the RCA in 32% of cases (CFX vs LAD or RCA, p=NS). Com- 
pared to pts with ST-elevation, in those with non-ST elevation ACS the CFX was more 
commonly the culprit vessel (40 vs 12%, p<0.001). The frequency of LAD and RCA cul- 
prits was similar between the two groups. Conclusions: These findings document a 
striking disparity in the prevalence of CFX culprits in pts with ST-eiavation MI compared 
to non-ST eiavatlon ACS. The rarity of CFX culprits in ST-alevation MI but even distribu- 
tion in other ACS, suggests that the CFX is just as likely to develop plaque rupture but 
that lateral wall transmural ischemia is often missed by ECG. 
1100-46 Does Prior Angina Predict Outcomes Following Acute 
Myocardial Infarction? Testing the Relevance of 
Ischemic Pre-Condi t ion ing in the Era of Pr imary  
Angioplasty 
Kishore J. Harjai, Cindv L. Grines. H. Mehrdad Sadeghi, Calvin Ledford, Dominic 
Marsalese, Judith Boura, Robert D. Safian, James A. Goldstein, Joel Kahn, William W. 
O'Neill, Primary Angiopiasty in Myocardial Infarction (PAMI) Group, William Beaumont 
Hospital, Royal Oak, Michigan. 
Background: In animal studies, brief periods of myocardial ischemia reduce the size of 
the infarct resulting from a subsequent total occlusion. It is postulated that angina pre- 
ceding acute myocardial infarction (AMI) may provide similar benefit in humans. How- 
ever, clinical studies on the prognostic impact of preinfarction angina have shown mixed 
results. 
Methods: We tested the effect of prior angina on in-hospital outcomes [ischemic target 
vessel revascularization (TVR), reinfarotion, death, & MACE (combined end-point)] in the 
pooled database of 2558 patients enrolled in Primary Angioplasty in Myocardial Infarction 
(PAMI)-2 &Stent PAMI trials. To minimize confounding from silent ischemia & atharoscle- 
rotic burden, we excluded 878 (34%) patients with a history of diabetes, pdor myocardial 
infarction, prior percutaneous coronary intervention or coronary artery bypass surgery 
from this analysis, In the remaining 1680 patients, we compared angiogrephic & clinical 
outcomes between patients with (n=230, 17%) & those without prior angina (n=1450, 
83%). 
Results: Prior angina patients had a higher incidence of hypertension (50 vs 40%), dys- 
lipidemia (45 vs 33%), peripheral vascular disease (5.7 vs 3.0%), & previous aspirin use 
(24 vs 9%, p<O.05 for all). The 2 groups had otherwise similar baseline clinical & anglo- 
graphic features. Stent use (29 vs 29%), final TIMI-3 flow (91 vs 92%), mean residual 
stenosis (22 vs 21%), & cath lab complications (33 vs 29%) were comparable between 
groups. Patients with prior angina had similar incidence of in-hospital reinfarotion (1.3 vs 
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0.8%), TVR (3.9 vs 2.8%), death (2.2 vs 2.8%), and MACE (6.1 vs 5.7%) as those with- 
out prior angina (P=NS for all). Further, during 1-year follow-up, no difference was found 
in the incidence of death (4.7 vs 5.6%, p=0.60) or MACE (23 vs 17%, p=0.07), between 
patients with and those without prior angina. 
Conclusions: A history of angina prior to acute myocardial infarction does not confer 
protection from adverse outcomes in patients undergoing primary angioplasty. Our find- 
ings challenge the clinical relevance of ischamic pre-conditioning in such patients. 
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1101 Risk Assessment and Management of 
Acute Coronaw Syndromes: Insights 
From Large Databases 
Monday, March 18, 2002, Noon-2:00 p.m. 
Georgia World Congress Center, Hall G 
Presentation Hour: 1:00 p.m.-2:00 p.m. 
1101-33 Characteristics and Outcome of Patients With ST 
Elevation Versus Non-ST Elevation Myocardial 
Infarction: Results of the MONICA Augsburg Myocardial 
Infarction Registry 1985-1995 
Bernhard Kuch, Heinz D. Bolte, Wolfgang von Scheidt, Hannelore L5wal, L Medizinische 
Klinik, Klinikum Augsburg, Augsburg, Germany, GSF-Forschungsinstitut, Neuherherg, 
Germany. 
Background: The classification of myocardial infarction (MI) has been more and more 
moved from discerning Q-wave from Non-Q-wave MI to classifying MI by ST- wave 
dynamics. Data about patient (pat.) characteristics and prognosis in relation to their ST- 
wave dynamics are scarce. Methods and Results: We, therefore, analyzed ECG-data 
(Minnesota-Coding) from the MONICA Augsburg Myocardial Infarction-Registry from 
1985-1995 (n= 2896; aged 25-75 years; 74% men). ST-Elevation MI (ST-E) was most 
frequent (59%), followed by MI with unspecific ST-changes (neither elevation or depres- 
sion; ST-U; 25%) and MI with ST-depression (ST-D; 16%). Pat. with ST-D were more 
often diabetics than pat. with ST-E or ST-U (28.1 vs. 21.9 and 20.5%; respectively), ware 
more often female (31.5 vs. 26.3 and 19.7%), had more often a history of angina (47.3 
vs. 36.7 and 40.0%) and previous MI (27.6 vs. 19.5 and 23.9%), and were less often 
treated by thrombolytics (13.6 vs. 38.8 and 12.4%; p for all comparisons < 0.001). In 
addition, pat. with ST-D were significantly older, had a higher mean pulse rate during 
admission, and a lower peak CK level than pat. with ST-E (p <0.01 respectively). The 28- 
day-case fatality-rate was 13.2% for ST-D, 10.8% for ST-E, and 7.5% for ST-U, respec- 
tivety (significance only for ST-E vs. ST-U; p < 0.001; for ST-E vs. ST-D p > 1). These 
case-fatality differences were not altered substantially by multivariate testing in a logistic 
regression model including the above mentioned ifferences in history and therapy. 
Conclusion: 25% of MI-pat. had a non-diagnostic ECG. This group has the lowest mortal- 
ity. Despite significant differences in presentation and cardiovascular isk-factor history, 
pat. with ST-elevation did not differ in terms of short-term prognosis from pat. with ST- 
depression. 
1101-34 Opportunities for Enhancing the Use of Evidence-Based 
Medicines for Acute Coronary Syndromes: Insights 
From the SYMPHONY Studies 
Judith Kramer. L. Kristin Newby, John Simes, Frans Van de Weft, Christopher Granger, 
Kerry Lee, Manjushri Bhapkar, Robert Califf, Paul W. Armstrong, University of Alberta, 
Edmonton, Alberta, Canada, Duke Clinical Research Institute, Durham, North Carolina. 
The extent to which evidence-basad therapy [Class IA or IB evidence (AHNACC 9/2000 
and ESC 9/2000)] is applied internationally to the broad cross-section of patients early 
after acute coronary syndromes (ACS) is unknown. Accordingly, we evaluated this issue 
in 15,904 patients from 36 countries entered into the Symphony and 2nd Symphony 
studies of sibrafiban between Aug 1997 and Aug 1999. We analyzed by geographic 
region the use of concomitant medications between each patient's qualifying ACS event 
and start of study treatment [median 91 hrs); and to what extent international variations 
in treatment could be explained by differences in patient risk profile. The data are shown 
in the Table. 
There were important variations in evidence-based treatment of ACS across geographic 
region, which remained highly significant (p<0.001) after adjustment for all major patient 
risk factors for future coronary events. Given the greater use of some treatments but 
lesser use of others within the same region, we believe these findings are unlikely to be 
driven by cost alone. Our data also indicate substantial global opportunities for improving 
secondary prevention. Hence continued monitoring of these international patterns of care 
and development of appropriate interventions to increase adherence to evidence-based 
~]uidelines i a desirable next step. 
Med Class Asia L.Amedca E.Europe W.Europe USA Canada Au/NZ 
n=551 n=557 n=2661 n=3431 n=7185 n=871 n=648 
ASA 87% 86% 75% 82% 85% 88% 91% 
Beta blockers 68% 75% 70% 69% 73% 78% 75% 
Lipid lowering 37% 17% 10% 30% 40% 29% 42% 
ACE inhibitors 56% 50% 48% 30% 33% 36% 33% 
Heparin 37% 61% 55% 52% 78% 79% 51% 
LMWH 27% 16% 28% 34% 10% 11% 34% 
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1101-35 Early Use of Glycoprotein 2b3a Inhibitors and 
Outcomes in Non-ST Elevation Mh Observations From 
the NRMI-4 
Eric D, Peterson, John G. Canto, Charles V. Pollack, Lori Parsons, Matt T. Roe, Kathee 
Littrell, Nathan R. Every, Hal V. Barron, for the NRMI-4 Investigators, Duke C/inica/ 
Research Institute, Durham, North Carolina. 
Background: The recent AHA/ACC ACS Guidelines recommend early use of glycopro- 
tein lib-Ilia inhibitors (GP 2b3a) in non-ST elevation MI (NSTEMI) patients, yet commu- 
nity adoption has been slow. 
Methods: We examined the relationship between "eady use" of GP 2b3a within 24hrs of 
admission and in-hospital mortality in 32,710 NSTEMI patients eligible for GP 263a, 
treated at 1,087 hospitals in the NRMI 4 Registry between July 2000-April 2001. 
Results: Overall, 24% of eligible NSTEMI patients were begun on a GP 2b3a in <24hrs. 
Patients treated with GP 2b3a <24 hrs were younger, more likely male, and had chest 
pain and ST depression on presentation than those not. Unadjusted in-hospital mortality 
rate was significantly lower in those treated with GP 2b3a <24hrs than those not treated 
early (3.2% vs 8.5%, p<0.0001). After adjusting for 13 patient risk factors (NRMI NSTEMI 
risk model, C-index 0.75), and for hospital size, region, teaching affiliation and cath facili- 
ties, patients getting GP 2b3a <24 hrs had 32% lower relative risk for in-hospital mortality 
(adjusted OR 0.68, 95% CI 0.59-0.79). Adjustment for treatment propensity (to receive 
GP 2b3a<24 hrs) revealed similar results. The Figure displays mortality rates by GP2b3a 
use <24hrs according to NRMI risk group. 
Conclusion: Early use of GP 2b3a within 24 hrs of admission was associated with lower 
in-hospital mortality across the NSTEMI risk spectrum. As only 24% of eligible patients 
received early GP2b3a therapy, there is considerable room for quality improvement. 
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1101-36 Comparison of Characteristics, Treatment, and 
Outcomes of Patients Enrolled Versus Not Enrolled in a 
Clinical Trial: Findings From TIMI 9 Registry and 9B 
Trial 
Maria Cecilia Bahit, Elliott M. Antman, Sabina A. Murphy, Carolyn H. McCabe, 
Christopher P. Cannon, Brigham and Women's Hospital, Boston, Massachusetts. 
Background: Because mortality in clinical trials (CT) is generally lower than in registries 
of clinical practice, it has been suspected that patients are lower risk. However, little is 
known about the characteristics of patients included vs. not in CT. Methods: To address 
this issue, TIMI 9 Registry prospectively evaluated characteristics and in-hospital out- 
comes for ST-elevation MI patients at 20 hospitals during the conduct of TIMI 9B trial.We 
compared characteristics, treatment and outcomes of patients in TIMI 9B trial (N=3002), 
with others eligible for thrombotysis but not enrolled in the TIMI 9B thai (N=296), and with 
those not-eligible for thrombolysis by ACC/AHA criteria at the same centers (N=282). 
Results: At TIMI 9 Registry hospitals, 46% of eligible patients were enrolled in TIMI 9B. 
Across the three groups, a gradient of both high-risk baseline characteristics, use of rep- 
effusion therapy and mortality was observed. In addition, although we did not assess 
contraindications for each medication, use of aspirin, (and beta-blockers, ACE inhibitors) 
both initially and at discharge was lower among eligible/not enrolled patients (p<0.0001 
for aspirin) or ineligible patients.(Tabla) 
Conclualon: In this prospective registry, we found that half of eligible patients were 
enrolled. Those not enrolled had higher risk characteristics and worse outcomes; how- 
ever, they also were treated less frequently with guideline-recommended medications, 
which may have contributed to their hi~lher mortality. 
Eligible/ Eligible/not Not eligible/ 3-way p 
enrolled enrolled not enrolled 
Age (years) 60.1 ± 11.9 62.3 ± 13.5 67.5 ± 12.6 <0.0001 
Female gender 25.1% 32.4% 39.5% <0.0001 
Aspirin 99.4% 91.5% 75.2% <0.0001 
Thrombolysis 99.6% 59.8% 22.5% <0.0001 
Primary PCI 0 12.5% 12.7% <0.0001 
In hospital death 5.1% 8.4% 19.8% <0.0001 
Death + MI+ Shock+ severe CHF 9.0% 15.9% 30.1% <0.0001 
1101-37 Approach After Thrombolytic Therapy: Invasive Versus 
Conservative Management: Global Registry of Acute 
Coronary Events 
Immad Sadiq, Harold L Dauerman, Robert J. Goldberg, Warner Klein, David Briagsr, Ph. 
Gabriel Steg, Gilles Montalescot, Josd L6pez-Send6n, Andrzej Budaj, Joel M. Gore, for 
the GRACE Investigators, Saint Vincent Hospital & University of Massachusetts Medical 
School, Worcester, Massachusetts, Medizinische Universitdtsklinik, Graz, Austria. 
Background: Thrombolytics (lyrics) reduce mortality of patients (pts) with acute ST seg- 
ment elevation MI (STE MI). However, the impact of a subsequent invasive strategy on 
outcomes has not been studied in an international population-based setting. 
Methods: 1,766 pts enrolled in GRACE with STE MI who received lytics were divided into 
